(Acetaminophen + hydrocodone bitartrate)IR is under clinical development by Acura Pharmaceuticals and currently in Phase I for Pain. According to GlobalData, Phase I drugs for Pain have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how (Acetaminophen + hydrocodone bitartrate)IR’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Acetaminophen + hydrocodone bitartrate)IR overview
Hydrocodone bitartrate is under development in combination with acetaminophen as an immediate release formulation for the treatment of moderate-to-severe pain. It is a fixed dose combination administered orally in a form of a immediate release tablet. Acetaminophen targets prostaglandin G/H synthase 2 and hydrocodone targets mu-type opioid receptor. It is based on Limitx technology.
Acura Pharmaceuticals overview
Acura Pharmaceuticals (Acura) is a specialty pharmaceutical company that researches, develops and commercializes products and technologies to prevent the abuse and misuse of medication. Acura’s proprietary technologies include, Aversion, Limitx, and Impede technology. The company’s Limitx technology helps to minimize the risks associated with drug overdose and Aversion technology is to address methods of abuse associated with opioid analgesics. Its Impede technology helps minimize the extraction and conversion of pseudoephedrine into methamphetamine. Its product portfolio includes Oxaydo, an opioid analgesic; Nexafed and Nexafed Sinus Pressure plus that contain pseudoephedrine. The company markets products in the US and Canada. Acura is headquartered in Palatine, Illinois, the US.
For a complete picture of (Acetaminophen + hydrocodone bitartrate)IR’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
